|
Jul 29
|
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency
|
|
Jul 25
|
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
|
|
Jul 15
|
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
|
|
Jun 26
|
Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada
|
|
Jun 26
|
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
|
|
Jun 16
|
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
|
|
Jun 13
|
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
|
|
Apr 8
|
KalVista licenses commercialisation rights for HAE to Kaken in Japan
|
|
Apr 8
|
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
|
|
Feb 24
|
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
Feb 21
|
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
|
|
Feb 10
|
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
|
|
Oct 4
|
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
|
|
Oct 2
|
High Growth Tech Stocks To Watch In The United States
|
|
Sep 30
|
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
|
|
Sep 26
|
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
|
|
Aug 29
|
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
|
|
Jun 18
|
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
|
|
May 1
|
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
|
|
Apr 22
|
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
|